Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 13
Submit an article Journal homepage
239
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents

Carl Zainaldina Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USACorrespondence[email protected]
View further author information
,
Sankalp Aroraa Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USAView further author information
,
Srilakshmi Bathinib Divison of Hematology/Oncology, Dept of Medicine, University of at Birmingham, Birmingham, AL, USAView further author information
,
Udita Guptaa Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USAView further author information
,
Vishruti Pandyac Divison of Preventive Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USAView further author information
,
Sejong Baec Divison of Preventive Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USAView further author information
,
Sarah Worthd Department of Pharmacy, University of Alabama at Birmingham, Birmingham, AL, USAView further author information
,
Kimo Bachiashvilib Divison of Hematology/Oncology, Dept of Medicine, University of at Birmingham, Birmingham, AL, USAView further author information
,
Ravi Bhatiab Divison of Hematology/Oncology, Dept of Medicine, University of at Birmingham, Birmingham, AL, USAView further author information
,
Kelly Godbyb Divison of Hematology/Oncology, Dept of Medicine, University of at Birmingham, Birmingham, AL, USAView further author information
,
Omer Jamyb Divison of Hematology/Oncology, Dept of Medicine, University of at Birmingham, Birmingham, AL, USAView further author information
,
Sravanti Rangarajub Divison of Hematology/Oncology, Dept of Medicine, University of at Birmingham, Birmingham, AL, USAView further author information
,
Barry Diamondd Department of Pharmacy, University of Alabama at Birmingham, Birmingham, AL, USAView further author information
,
Josh D. Oliverd Department of Pharmacy, University of Alabama at Birmingham, Birmingham, AL, USAView further author information
,
Donna Salzmanb Divison of Hematology/Oncology, Dept of Medicine, University of at Birmingham, Birmingham, AL, USAView further author information
,
Antonio Di Stasib Divison of Hematology/Oncology, Dept of Medicine, University of at Birmingham, Birmingham, AL, USAView further author information
&
Pankit Vachhanib Divison of Hematology/Oncology, Dept of Medicine, University of at Birmingham, Birmingham, AL, USAView further author information
 show all
Pages 3245-3248 | Received 05 May 2022, Accepted 02 Aug 2022, Published online: 15 Sep 2022

References

  • DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
  • Maiti A, DiNardo CD, Qiao W, et al. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: a propensity score-matched analysis. Cancer. 2021;127(22):4213–4220.
  • Tenold ME, Moskoff BN, Benjamin DJ, et al. Outcomes of adults with relapsed/refractory acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a comprehensive cancer center. Front Oncol. 2021;11:649209.
  • DiNardo CD, Maiti A, Rausch CR, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-Centre, phase 2 trial. Lancet Haematol. 2020;7(10):e724–e736.
  • Aldoss I, Yang D, Aribi A, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018;103(9):e404–e407.
  • Bewersdorf JP, Giri S, Wang R, et al. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and Meta-analysis. Haematologica. 2020;105(11):2659–2663.
  • Maiti A, Rausch CR, Cortes JE, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021;106(3):894–898.
  • Zucenka A, Pileckyte R, Trociukas I, et al. Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies. Eur J Haematol. 2021;106(1):105–113.
  • Saliba AN, John AJ, Kaufmann SH. Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia. CDR. 2020;4(1):125–142.
  • DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791–803.
  • Zhang Q, Riley-Gillis B, Han L, et al. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022;7(1):51.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.